- Home
- MFA vs PHAR Comparison
MFA vs PHAR Comparison
Compare MFA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- PHAR
- Stock Information
- Founded
- MFA 1997
- PHAR 1988
- Country
- MFA United States
- PHAR Netherlands
- Employees
- MFA N/A
- PHAR N/A
- Industry
- MFA Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- PHAR Health Care
- Exchange
- MFA Nasdaq
- PHAR Nasdaq
- Market Cap
- MFA 1.0B
- PHAR 951.7M
- IPO Year
- MFA N/A
- PHAR N/A
- Fundamental
- Price
- MFA $9.73
- PHAR $13.86
- Analyst Decision
- MFA Buy
- PHAR Strong Buy
- Analyst Count
- MFA 8
- PHAR 3
- Target Price
- MFA $11.50
- PHAR $30.00
- AVG Volume (30 Days)
- MFA 1.1M
- PHAR 13.2K
- Earning Date
- MFA 11-05-2025
- PHAR 10-23-2025
- Dividend Yield
- MFA 14.79%
- PHAR N/A
- EPS Growth
- MFA 41.64
- PHAR N/A
- EPS
- MFA 0.88
- PHAR N/A
- Revenue
- MFA $284,489,000.00
- PHAR $339,836,000.00
- Revenue This Year
- MFA N/A
- PHAR $16.63
- Revenue Next Year
- MFA $16.86
- PHAR $6.77
- P/E Ratio
- MFA $11.06
- PHAR N/A
- Revenue Growth
- MFA 9.37
- PHAR 22.44
- 52 Week Low
- MFA $7.85
- PHAR $7.31
- 52 Week High
- MFA $13.45
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- MFA 41.50
- PHAR 51.52
- Support Level
- MFA $10.15
- PHAR $13.63
- Resistance Level
- MFA $10.57
- PHAR $15.27
- Average True Range (ATR)
- MFA 0.19
- PHAR 0.98
- MACD
- MFA -0.07
- PHAR -0.17
- Stochastic Oscillator
- MFA 6.67
- PHAR 16.68
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.